

# The Evolution of Biopharmaceuticals: Risk Assessment and Clinical Relevance

## Session 2: High Risk Drug Products – IVIVC/IVIVR

<i>Introduction:</i>	<b>Haritha Mandula, PhD</b>	Acting Supervisor, DPQA VI, OPQA I, OPQ, CDER, FDA
<i>Presenters:</i>	<b>Rajesh Savkur, PhD</b>	Senior Assessor, DPQA VI, OPQA I, OPQ, CDER, FDA
	<b>Yihong Qiu, PhD</b>	Chief Technical Director, QPD Solutions
	<b>Sanjaykumar Patel, PhD</b>	Senior Principal Scientist, Merck & Co., Inc.
	<b>David Sperry, PhD</b>	Executive Director, Synthetic Molecule Design & Development, Eli Lilly
<i>Summary:</i>	<b>Haritha Mandula, PhD</b>	Acting Supervisor, DPQA VI, OPQA I, OPQ, CDER, FDA